Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Cardiac Biomarkers Market Size Changed, over the years?

In recent years, the size of the cardiac biomarkers market has seen a swift expansion. It is predicted to rise from $18.99 billion in 2024 to $21.32 billion in 2025, with a compound annual growth rate (CAGR) of 12.3%. Factors such as elevated healthcare expenditure, FDA approvals and regulatory backing, an aging populace, awareness campaigns, high sensitivity troponin tests, and a surge in cardiovascular diseases are responsible for the growth experienced in the historic period.

How Much Will the Cardiac Biomarkers Market Be Worth in 2029?

The market size of cardiac biomarkers is forecasted to experience significant growth in the upcoming years, predicted to reach “$36.51 billion by 2029 with a compound annual growth rate (CAGR) of 14.4%. Reasons for this growth during the forecast period include the increasing prevalence of chronic diseases, a greater focus on early disease identification, an aging population, developing emerging markets, and a concentration on biomarker panels. Key trends predicted during this period encompass patient-focused healthcare models, the use of AI and machine learning, integration of digital health, technological advancements in biomarker discovery, multi-marker panels, and the use of liquid biopsy in cardiovascular medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

Which is the Largest Company in the Cardiac Biomarkers Market?

Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics

What Are the Main Market Drivers in the Cardiac Biomarkers Industry?

The escalating incidence of cardiovascular ailments is set to fuel the expansion of the cardiac biomarker market. Such ailments, which impair the heart and blood vessels, encompass coronary artery disease, heart failure, and stroke among others. Cardiac biomarkers, which are provoked into the bloodstream by certain cardiovascular diseases such as myocardial infarction (heart attack), heart failure, and arrhythmias, can be quantified via laboratory tests. These levels can yield significant diagnostic and prognostic details. For example, data released by the British Heart Foundation in September 2024 revealed that around 7.6 million people in the UK, including approximately 4 million men and 3.6 million women, suffer from heart and circulatory diseases. These disorders play a role in about 27% of UK deaths, resulting in over 170,000 deaths each year or roughly 480 deaths daily, which amounts to a death every three minutes. Consequently, the increasing incidence of cardiovascular diseases is accelerating the expansion of the cardiac biomarker market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10234&type=smp

How Is the Cardiac Biomarkers Market Segments Structured?

The cardiac biomarkers market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types

2) By Location Of Testing: Point Of Care Testing, Laboratory Testing

3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications

4) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels

2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels

3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels

4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels

5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels

6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers

What Strategic Trends Are Transforming the Cardiac Biomarkers Market?

The cardiac biomarker market is witnessing an uptick in cutting-edge technological practices, a trend predominantly triggered by corporations striving to maintain their influence in the sector. As part of this, the medical devices firm based in China, Mindray, unveiled novel high-sensitivity cardiac biomarkers troponin I (hs-cTnI) and NT-proBNP in October 2023, aiming to boost the diagnosis and control of cardiovascular diseases (CVDs). The hs-cTnI biomarker is crucial for detecting myocardial injury, thanks to its remarkable detection capabilities and minimal imprecision, making it ideal for early screening and risk evaluation in circumstances such as Acute Coronary Syndrome (ACS). Conversely, NT-proBNP stands as a reputable marker for heart failure, aiding its identification and management, while exhibiting outstanding precision and limited disruption from commonly prescribed heart drugs. Collectively, these biomarkers significantly enhance clinical decisions related to urgent cardiovascular treatments.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

Which Global Regions Offer the Highest Growth in the Cardiac Biomarkers Market?

North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10234

This Report Delivers Insight On:

1. How big is the cardiac biomarkers market, and how is it changing globally?

2. Who are the major companies in the cardiac biomarkers market, and how are they performing?

3. What are the key opportunities and risks in the cardiac biomarkers market right now?

4. Which products or customer segments are growing the most in the cardiac biomarkers market?

5. What factors are helping or slowing down the growth of the cardiac biomarkers market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model